September 26, 2024 03:00 PM EDT

AstraZeneca's lung cancer blockbuster Tagrisso wins label expansion in early-stage EGFR patients

Nicole DeFeudis

Editor

AstraZeneca’s blockbuster lung cancer treatment Tagrisso scored a new FDA approval on Thursday in certain EGFR-mutated early-stage patients whose non-small cell lung cancer has not …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca's lung cancer blockbuster Tagrisso wins label expansion in early-stage EGFR patients

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatry

Updated: FDA adcomm votes to limit Opdivo, Keytruda use in stomach, esophageal cancers based on key biomarker

ARCH, biotech's star slugger, snags another $3B for 13th fund

Insilico Medicine, an early force in AI-driven drug R&D, lets IPO plans peter out for second year in a row

Flagship launches startup to design and make lipid nanoparticles for genetic medicines

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

As­traZeneca's lung can­cer block­buster Tagris­so wins la­bel ex­pan­sion in ear­ly-stage EGFR pa­tients

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

AstraZeneca's lung cancer blockbuster Tagrisso wins label expansion in early-stage EGFR patients